Bronchodilators, fatal asthma, rebound effect and similitude

Homeopathy

Volumn 96, Issue 2, 2007, Pages 135-137

  Teixeira, Marcus Zulian ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; SALMETEROL;

AFRICAN AMERICAN; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CAUCASIAN; DEATH; DRUG FATALITY; HIGH RISK POPULATION; HOMEOPATHY; HOSPITALIZATION; HUMAN; LETTER; REBOUND; RISK ASSESSMENT; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ASPIRIN; ASTHMA; BRONCHIAL SPASM; BRONCHODILATOR AGENTS; EVIDENCE-BASED MEDICINE; HOMEOPATHY; HUMANS; IATROGENIC DISEASE; LACTONES; MATERIA MEDICA; SULFONES;

EID: 34147152787     PISSN: 14754916     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.homp.2007.02.001     Document Type: Letter

References (29)

1. Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 95 (2006) 229-236
2. Teixeira M.Z. Letter to the Editor: NSAIDs, Myocardial infarction, rebound effect and similitude. Homeopathy 96 (2007) 67-68
3. Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 96 (2007) 67-68
4. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
5. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
6. Kraan J., Koeter G.H., vd Mark T.W., Sluiter H.J., and de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 76 (1985) 628-636
7. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 (1990) 1391-1396
8. Lipworth B.J. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf 7 (1992) 54-70
9. Wahedna I., Wong C.S., Wisniewski A.F., Pavord I.D., and Tattersfield A.E. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis 148 (1993) 707-712
10. Suissa S., Blais L., and Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 7 (1994) 1602-1609
11. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 (2004) 802-813
12. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 158 Pt 3 (1998) S146-S153
13. van Schayck C.P., Bijl-Hofland I.D., Cloosterman S.G., Folgering H.T., van der Elshout F.J., and Van Weel C. Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma. Eur Respir J 19 (2002) 240-245
14. Newcomb R., Tashkin D.P., Hui K.K., Conolly M.E., Lee E., and Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am Rev Respir Dis 132 (1985) 12-15
15. Vathenen A.S., Knox A.J., Higgins B.G., Britton J.R., and Tattersfield A.E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1 (1988) 554-558
16. de Jong J.W., van der Mark T.W., Koeter G.H., and Postma D.S. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. Am J Respir Crit Care Med 153 (1996) 70-75
17. Hancox R.J., Cowan J.O., Flannery E.M., Herbison G.P., McLachlan C.R., and Taylor D.R. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med 94 (2000) 767-771
18. Stolley P.D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105 (1972) 883-890
19. Baagoe K.H. The epidemic of asthma mortality in the 1960's. Aerosol spray as cause of the deaths. Ugeskr Laeger 138 (1976) 2708-2711
20. Keating G., Mitchell E.A., Jackson R., Beaglehole R., and Rea H. Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81. Br Med J (Clin Res Ed) 289 6441 (1984) 348-351
21. Mormile F., Chiappini F., Feola G., and Ciappi G. Deaths from asthma in Italy (1974-1988): Is there a relationship with changing pharmacological approaches?. J Clin Epidemiol 49 (1996) 1459-1466
22. Pearce N., Beasley R., Crane J., Burgess C., and Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 345 (1995) 41-44
23. Beasley R., Pearce N., Crane J., and Burgess C. Beta-agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality?. J Allergy Clin Immunol 104 Pt 2 (1999) S18-S30
24. Hussey P.S., Anderson G.F., Osborn R., et al. How does the quality of care compare in five countries?. Health Aff (Millwood) 23 (2004) 89-99
25. Patterns of medication use in the United States 2004. A report from the Slone Survey. Boston: Slone Epidemiology Center at Boston University; 2004. Available on: 〈http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyReport2004.pdf〉.
26. The World Factbook. United States. Washington, DC: Central Intelligence Agency; 2005.
27. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Program Description. Bethesda, MD: National Institute of Health; 2005.
28. Humbert M. The right tools at the right time. Chest 130 Suppl 1 (2006) 29S-40S
29. Denlinger L.C., Sorkness C.A., Chinchilli V.M., and Lemanske Jr. R.F. Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network. J Allergy Clin Immunol 119 (2007) 3-11